Skip to main content

Table 1 Available targeted agents in advanced gastric cancer

From: The progress of targeted therapy in advanced gastric cancer

NCT code/trial name

Drugs

Setting

Masking

Primary endpoint

Arm

Status

Results

PhaseIIIToGA/NCT01041404

HER2 inhibitor

Trastuzumab

First line

Double blind

OS

Cisplatin + fluoropyrimidine + Trastuzumab vs. Placebo

Finished

Positive

PhaseIIINCT01774786

Pertuzumab

First line

Double blind

OS

Trastuzumab + cisplatin + fluoropyrimidine + Pertuzumab vs. Placebo

Ongoing

Unknown

Phase III/IIINCT01641939

T-DM1

Second line

Open label

OS

T-DM1 vs. Taxane

Ongoing

Unknown

PhaseIII TYTAN/NCT00486954

Lapatinib

Second line

Open label

OS

Lapatinib vs. Paclitaxel

Finished

Negative

PhaseIII LOGiC/NCT00680901

Lapatinib

First line

Double blind

OS

Capecitabine + oxaliplatin + Lapatinib vs. Placebo

Finished

Negative

PhaseIIIEXPAND/NCT00678535

EGFR Inhibitors

Cetuximab

First line

Open label

PFS

Capecitabine and cisplatin + Cetuximab vs. Placebo

Finished

Negative

PhaseIIIREAL-3/NCT01234324

Panitumumab

First line

Open label

Frequency of pT3/T4 categories after surgery

EOX (epirubicin/oxaliplatin/capecitabine)

Ongoing

Unknown

PhaseIII AVAGAST/NCT00548548

VEGF inhibitors

Bevacizumab

First line

Double blind

OS

Capecitabine + cisplatin + Bevacizumab vs. Placebo

Finished

Negative

PhaseIII REGARD/NCT00917384

Ramucirumab

Second line

Double blind

OS

and BSC + Ramucirumab vs. Placebo

Finished

Positive

PhaseIIIRAINBOW/NCT01170663

Ramucirumab

Second line

Double blind

OS

Paclitaxel + Ramucirumab vs. Placebo

Ongoing

Unknown

PhaseIIINCT01246960

Ramucirumab

First line

Double blind

PFS

mFOLFOX6+ Ramucirumab vs. Placebo

Ongoing

Unknown

PhaseIIINCT00970138

Apatinib

Third line

Double blind

PFS

Placebo vs.Apatinib

Finishes

Positive

PhaseIIINCT01512745

Apatinib

Third line

Double blind

PFS

placebo vs. apatinib

Ongoing

Unknown

PhaseIIINCT01747551

Aflibercept

First line

Double blind

PFS

mFOLFOX6 + Aflibercept vs. Placebo

Ongoing

Unknown

PhaseIIINCT01152645

c-MET inhibitor

Tivantinib (ARQ 197)

Second/Thirdline

Open label

DCR

Tivantinib

Finished

Modest efficacy

PhaseIIINCT01662869

Onartuzumab

First line

Double blind

OS

mFOLFOX6 + Onartuzumab vs. Placebo

Ongoing

Unknown

PhaseIIIGRANITE-1/NCT00879333

m-TOR inhibitor

Everolimus (RAD001)

Second/third line

Double blind

OS

Everolimus vs. Placebo

Finished

Negative

  1. Abbreviation: HER2 human epidermal growth factor receptor-2, OS overall survival, EGFR epidermal growth factor receptor, PFS progression free survival, VEGF vascular endothelial growth factor, BSC best supportive care, DCR disease control rate, m-TOR mammalian target of rapamycinm.